BlueWind Medical, a medical device company focused on transforming neuromodulation therapy for urge urinary incontinence, has successfully closed a $47.8M Series B funding round. The capital infusion will accelerate the development and deployment of its innovative approach.
The company's core technology centers on a miniature tibial neuromodulation (iTNM) device. This device is designed for implantation near the ankle in a minimally invasive outpatient procedure, offering a patient-centric system that allows for therapy customization to enhance individual response.














